Acadia Pharma (NASDAQ: ACAD) is fading early ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Momentum Movers Trader Talk

Aegis Capital Affirms Acadia Pharma (ACAD) at 'Buy' Following Positive FDA Panel Review; Sees Nuplazid Approval SoonMarch 30, 2016 10:44 AM Needham & Company Remains Bullish on Acadia Pharma (ACAD) Following Positive FDA Vote on Nuplazid March 30, 2016 6:49 AM Acadia Pharmaceuticals (ACAD) PT LIfted to $44 at Piper Jaffray Amid Panel Backing for NUPLAZIDMarch 30, 2016 6:26 AM Acadia Pharma (ACAD) Announces Favorable FDA Panel Vote on NUPLAZID for the Treatment of Psychosis Associated with Parkinson's DiseaseMarch 29, 2016 5:14 PM FDA Advisory Committee Votes 12 to 2 That Benefits of ACADIA Pharmaceuticals’ NUPLAZID™ (Pimavanserin) for the Treatment of Psychosis Associated with Parkinson’s Disease Outweigh the RisksMarch 29, 2016 5:13 PM Acadia Pharma (ACAD) wins FDA panel backing for Nuplazid - BloombergMarch 29, 2016 3:37 PM